Technical Analysis with a Quantitative Edge

SIGN UP  |  LOGIN

HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

Merrimack Pharmaceuticals, Inc. (MACK)
Equity - Health Care - Major Pharmaceuticals

 

As of 2017-12-15

Add to My Portfolio
Close10.35Open10.19
Prev Close10.18Daily Chg+0.17 (+1.67%)
High10.49Volume443,985
Low10.1052-Week High/Low15.09 / 1.16
Dividend Yield0%Curr P/E0.37
Curr Year EPS Est33.49Fwd P/E0.35
P/B1.47Short Ratio18.07
P/S1.09PEG Ratio0.06
Latest QuantForecast
As Of
Customize QuantForecast   View Commentary & Pattern   Save To My Forecasts     Share

 
 
 

SUPPORT
Lower Boll Band: 9.71 100SMA: 9.45 200SMA: 5.97
RESISTANCE
9EMA: 10.53 20SMA: 11.19 50SMA: 11.88
COMMENTARY
Trend is deteriorating although remain in a long-term uptrend . However, Momentum is improving with Slow Stochastics turning higher and Fast Stochastics turning higher. Near-term technicals are oversold with Slow Stochastics near historical low. Forecast points to higher price but with choppy action
TECHNICAL PATTERN

TYPEDESCRIPTION (?)CRITERIA (?)
Positive Divergence Price is Moving Lower while Slow Stochastics is crossing Positively Slow Stochastics K Line > Slow Stochastics D Line and 10-Day Chg is Below Zero
Positive Divergence Price is Moving Lower while Fast Stochastics is crossing Positively Fast Stochastics K Line > Slow Stochastics K Line and 10-Day Chg is Below Zero
Negative Momentum RSI is Trending Lower in the last 10 Days RSI 10SMA Trend < 0
Short-Term Down Trend 9-Day Exponential Moving Average is Trending Lower 9EMA Trend < 0
Short-Term Down Trend 20-Day Simple Moving Average is Trending Lower 20SMA Trend < 0
Oversold Condition Slow Stochastics D Line near historical low at 10.65, occurred 7.88% of the time Slow Stochastics D Line = 10.65 +- 0.86
FORECAST STATISTICS
TIMEFRAME 2-DAY 5-DAY 10-DAY 20-DAY
Average -0.58% +3.71% +1.99% +4.78%
Best +13.29% +14.41% +14.96% +14.34%
Worst -12.23% -7.14% -10.58% -12.33%
% Positive 38% 50% 50% 75%
Outlook BEARISH NEUTRAL NEUTRAL BULLISH
HISTORICAL MATCHES (?)
MATCH DATE 2-DAY 5-DAY 10-DAY 20-DAY
2017-12-15 0% 0% 0% 0%
2016-08-15 -6.83% -2.47% -9.87% -12.33%
2016-05-03 -0.60% 0.00% -3.15% +0.90%
2016-05-02 -12.23% -7.14% -10.58% -8.38%
2015-06-16 +13.29% +14.41% +14.96% +7.16%
2015-06-15 +1.28% +12.55% +8.97% +8.70%
2014-07-29 -0.17% +0.17% +12.67% +13.85%
2014-02-04 -8.76% 0.00% -3.78% +14.34%
2012-11-02 +9.35% +12.15% +6.70% +14.02%
# Matches 8
TRADE SIGNALS ?
POSITIONENTRY DATEENTRY PRICETARGET PRICE (?)STOP PRICE (?)CURRENT PNL %
Premium Members Only

Upgrade Now & Subscribe to Daily Trade Signals

CLOSED TRADES
POSITIONENTRY DATEENTRY PRICEEXIT DATE EXIT PRICEREALIZED PNL %
Short 2016-03-21 8.30 2016-04-28 7.29 +12.17%
Long 2014-04-29 4.49 2014-05-08 6.38 +42.09%
Related Stocks
SYMBOL NAME Close VOLUME CHG WTD MTD YTD QUANTFORECAST(?)
2-DAY 5-DAY 10-DAY 20-DAY
JNJ Johnson & Johnson 142.42 7,111,931 +0.70 (+0.49%) +1.87 (+1.33%) +3.09 (+2.22%) +27.96 (+24.42%)
PFE Pfizer, Inc. 37.20 23,896,984 +0.71 (+1.96%) +1.46 (+4.07%) +0.95 (+2.64%) +5.35 (+16.79%)
MRK Merck & Company, Inc. 56.22 12,845,029 +0.18 (+0.32%) +0.65 (+1.17%) +0.96 (+1.74%) -2.22 (-3.80%)
SNY Sanofi 43.11 1,303,231 +0.07 (+0.15%) -0.14 (-0.32%) -2.54 (-5.58%) +2.67 (+6.59%)
ABBV AbbVie Inc. 97.44 5,209,292 +1.14 (+1.18%) +1.48 (+1.54%) +0.54 (+0.56%) +36.08 (+58.80%)
>>> See More Related Stocks
LATEST BUZZ
@cctranscripts
Posted 2017-12-18T12:22:19Z
Merrimack Pharmaceuticals just filed its Current report, item 8.01 http://www.conferencecalltranscripts.org/include?location=http://www.sec.gov/Archives/edgar/data/1274792/000095012317011384/0000950123-17-011384-index.htm $MACK
@Lmmadic
Posted 2017-12-18T10:20:00Z
$MACK so what are your expectations for the stock today? personally expecting drop and bounce. But unsure for direction towards friday.
@EstimizeAlerts
Posted 2017-12-18T05:18:12Z
Estimize EPS expectations are 46.69% lower than that of Wall Street for $MACK Q4 [Reporting 02/28 BMO] http://www.estimize.com/intro/mack?utm_content=MACK&amp;utm_medium=eps_difference&amp;utm_source=stocktwits#chart=change-over-time
@TheCrownedPixel
Posted 2017-12-18T04:07:37Z
$MACK pretty terrible if management has known about any issues with trials, and has continued to try and operate this company this way.
@ChartMill
Posted 2017-12-17T23:34:06Z
$MACK has a poor technical rating and the quality of the setup is also only medium at the moment. We see reduce ... https://www.chartmill.com/analyze.php?utm_source=stocktwits&utm_medium=TA&utm_content=SETUP#/MACK?key=0edd302d-c7a1-479d-a7ec-80d54e66c2fe
@marcopus26
Posted 2017-12-17T18:53:29Z
$MACK how are you bullish on this crap. been going down for over a year
@robredom
Posted 2017-12-17T15:59:35Z
$MACK does anyone know the authorized additional shares? Up to 20 million?
@scistats
Posted 2017-12-17T13:07:54Z
$MACK "INNOVATION DOESN'T HAPPEN ALONE."(ATRinhibitor,Nanoliposome targeting ATR) for ARID1A deficient tumors.Partner:VertexPharmaceuticals?
@Alex_Jones
Posted 2017-12-16T23:16:49Z
$SGYP Explain yourself fool. You brought it up. Now explain yourself coward. How is this in any way similar to $MACK ? You’re a coward.
@scistats
Posted 2017-12-16T23:00:22Z
$MACK CEO Peters M.D. needs to walk us through this in a CC.
@scistats
Posted 2017-12-16T22:59:25Z
$MACK "This represents an immediate increase in net tangible book value of approximately $0.37 per share to our existing stockholders"
@Alex_Jones
Posted 2017-12-16T22:26:03Z
@anton61 a drug that failed its phase2 drug study MM302 in HER2+metastatic breast ca. $MACK had been hoping to partner this asset
@scistats
Posted 2017-12-16T15:46:46Z
$MACK David Meek wanted MM-121 (seribantumab), and he just might get it. Ipsen ties run deep. ATRi will tell the tale.
@scistats
Posted 2017-12-16T15:41:17Z
$MACK My guess for partnership announcement date is no later than the end of this coming March. IMHO.
@scistats
Posted 2017-12-16T15:38:25Z
$MACK IMHO ATRi-nanoliposome collaboration either Vertex or Ipsen. Combo for BC will include MRI patient selection Intralipid & photopriming
@scistats
Posted 2017-12-16T15:34:11Z
$MACK ATR inhibitor in a nanoliposome collaboration may be with Ipsen because ATRi+MM-398 combo mentioned heavily in patent WO/2017/123588
@movam
Posted 2017-12-16T15:32:31Z
$MACK WTF - that's all I have to say! Pls don't reply to this.
@Alex_Jones
Posted 2017-12-16T14:13:47Z
$MACK No one said impossible. Perhaps you should partake in a reading compression course.
@ChartMill
Posted 2017-12-16T10:30:06Z
$MACK has a poor technical rating and the quality of the setup is also not perfect at the moment. Prices have b ... https://www.chartmill.com/analyze.php?utm_source=stocktwits&utm_medium=TA&utm_content=SETUP#/MACK?key=0edd302d-c7a1-479d-a7ec-80d54e66c2fe
@EstimizeAlerts
Posted 2017-12-16T10:05:14Z
$MACK estimates distribution - here’s what 3 Estimize analysts are expecting $MACK to report for Q4 [Reporting 02/28 BMO] http://www.estimize.com/intro/mack?utm_content=MACK&amp;utm_medium=distribution&amp;utm_source=stocktwits#chart=scatter-plot
MACK LATEST NEWS
Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
Posted Mon, 11 Dec 2017 11:30:26 Z
It has been more than a month since the last earnings report for Merrimack Pharmaceuticals Inc MACK Shares have lost about 7 8 in the past month underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a... >>> Read More
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
Posted Thu, 09 Nov 2017 17:15:42 Z
Merrimack Pharmaceuticals Inc MACK reported a loss of 40 cents per share in the third quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 1 88 The company had reported a loss of 2 06 in the year ago quarter Merrimack sold Onivyde and a generic version of Doxil to... >>> Read More
Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
Posted Wed, 08 Nov 2017 15:17:41 Z
Cambridge MA based Merrimack Pharmaceuticals Inc MACK is a biopharmaceutical company focused on the discovery development and commercialization of innovative therapies in combination with companion diagnostics for the treatment of cancer With sale of Onivyde Merrimack is now... >>> Read More
Earnings Reaction History: Merrimack Pharmaceuticals Inc, 33.3% Follow-Through Indicator, 4.3% Sensitive
Posted Wed, 08 Nov 2017 12:11:02 Z
Expected Earnings Release 11 08 2017 PremarketExpected Earnings Release 11 08 2017 Premarket Avg Extended Hours Dollar Volume 645 825Avg Extended Hours Dollar Volume 645 825 Merrimack Pharmaceuticals Inc MACK is due to issue its quarterly earnings report in the... >>> Read More
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
Posted Mon, 06 Nov 2017 17:10:51 Z
Merrimack Pharmaceuticals Inc MACK is expected to report third quarter 2017 results around Nov 8 before market opens Last quarter Merrimack missed bottom line expectations by 57 14 Merrimack s share price has decreased 71 3 year to date against the industry s gain of 3... >>> Read More

WINGCHARTS.COM    HOW IT WORKS    TRADE SIGNALS    SCREENER    MY PORTFOLIO    HELP

 



Follow Us on StockTwits
Partners / Affiliates

Copyright © 2017 WingCapital Co., Ltd. All Rights Reserved.

Disclaimer: Past results are not necessarily indicative of future performance. This website is for educational purposes only. No content published in this website, services and products constitutes a recommendation that any particular investment, security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Practical use of the content, forecasts, charts and services provided in this website are at your own risk and WingCapital Co., Ltd., WingCharts.com, its partners, representatives and employees assume no responsibility or liability for any use of the website. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Trade signals shown are hypothetical and do not represent actual trades. Actual results may differ. Views, forecasts and commentaries expressed in this website are WingCapital Co., Ltd.'s own opinions, and are not guarantees of future performance, and are subject to change over time.

WingCharts.com and WingCapital Co., Ltd. are not registered investment advisor or a broker dealer and do not give individualized market advice. The information on this website is for illustration purposes only and should not be considered as a solicitation of an offer on the purchase or sale of any securities. Trading in the securities markets involves substantial risk and should not be undertaken without due diligence and serious independent study. WingCapital Co., Ltd. recommends consulting a licensed professional broker regarding your personal investments. Without limitation, WingCapital Co., Ltd. shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscribers inability to use or any delay in accessing the WingCharts.com website or any other source of material provided by WingCharts.com and WingCapital Co., Ltd.; (3) any absence or error of material on WingCharts.com website or presentation; (4) WingCapital Co., Ltd. failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material.

ALL INFORMATION AND MATERIALS ARE PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.